All In MedTech

FDA Clearance Tracker · P210029

Aptima CMV Quant Assay

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: May 9, 2022 (this decision)Source: openFDAMethods & limitations

PMA

Decided

May 9, 2022

Approved (reclassified)

Time to decision

287 days

Received Jul 26, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class II

The decision

FDA number
P210029
Device name
Aptima CMV Quant Assay
Applicant
Hologic, Inc.
Applicant location
San Diego, CA
Received
Jul 26, 2021
Decided
May 9, 2022
Decision
Approved (reclassified)
Supplements
2 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class II
Regulation
21 CFR 866.3180

Every decision under product code PAB

FDA's approval statement

As written in FDA's record.

Approval of The Aptima CMV Quant Assay - This device is approved for:The Aptima CMV Quant Assay is an in vitro nucleic acid amplification test for the quantitation of human cytomegalovirus (CMV) DNA in human EDTA plasma on the fully automated Panther system. The Aptima CMV Quant Assay is intended for use to aid in the management of solid-organ transplant patients and hematopoietic stem cell transplant patients. In patients receiving anti-CMV therapy, serial DNA measurements can be used to assess viral response to treatment. The results from Aptima CMV Quant Assay must be interpreted within the context of all relevant clinical and laboratory findings.Aptima CMV Quant Assay is not intended for use as a screening assay for the presence of CMV in blood or blood products.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code PAB. The earliest in FDA's data is P110037, decided Jul 5, 2012.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Hologic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.